natgillin/translations-raw huggingface dataset:
carbohydrates), - you lose carbohydrates due to vomiting or diarrhoea, - you drink alcohol, particularly if you are not eating much, - you are doing more exercise than usual or a different type of physical activity, - you are recovering from an injury or operation or other stress, - you are recovering from an illness or from fever, - you are taking or have stopped taking certain other medicines (see section 2, "Other medicines and ABASAGLAR").
- ako pijete alkohol, osobito ako ne jedete dovoljno - ako vježbate više nego obično ili se bavite drugačijom vrstom tjelesne aktivnosti - ako se oporavljate od ozljede, operacije ili nekog drugog stresa
- If you have injected too much ABASAGLAR, your blood sugar level may become too low (hypoglycaemia).
Ako ste injicirali previše lijeka ABASAGLAR, razina šećera u krvi može postati preniska (hipoglikemija).
HYPERGLYCAEMIA AND HYPOGLYCAEMIA Always carry some sugar (at least 20 grams) with you.
Uvijek sa sobom nosite malo šećera (barem 20 grama).
The patient should be advised to read the instructions for use included in the package leaflet carefully before using ABASAGLAR solution for injection in pre-filled pen.
Bolesnika treba uputiti da prije uporabe ABASAGLAR otopine za injekciju u napunjenoj brizgalici pažljivo pročita upute za uporabu brizgalice, koje se nalaze u uputi o lijeku.
Do not use ABASAGLAR KwikPen if you notice particles in it. Only use ABASAGLAR KwikPen if the solution is clear, colourless and water-like.
Brizgalicu ABASAGLAR KwikPen smijete upotrijebiti samo ako je otopina bistra, bezbojna i vodenasta.
Each cartridge contains 3 mL of solution for injection, equivalent to 300 units.
Jedna brizgalica sadrži 3 ml otopine za injekciju, što odgovara 300 jedinica.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING INTERMEDIATE CARTON of a multipack (without blue box) - KwikPen
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU MEĐUPAKIRANJE višestrukog pakiranja (bez plavog okvira) - KwikPen brizgalica
This is a modified insulin, very similar to human insulin.
ABASAGLAR sadrži inzulin glargin.To je modificirani inzulin, vrlo sličan ljudskom inzulinu.
Solution for injection 5 cartridges of 3 mL.
Otopina za injekciju 5 uložaka od 3 ml 10 uložaka od 3 ml
These include patients: - in whom glycaemic control is markedly improved, - in whom hypoglycaemia develops gradually, - who are elderly, - after transfer from animal insulin to human insulin, - in whom an autonomic neuropathy is present, - with a long history of diabetes, - suffering from a psychiatric illness, - receiving concurrent treatment with certain other medicinal products (see section 4.5).
- u kojih je regulacija glikemije izrazito poboljšana, - u kojih se hipoglikemija razvija postupno, - starije životne dobi, - koji su prešli sa životinjskog inzulina na ljudski inzulin, - u kojih je prisutna autonomna neuropatija,
Giving your injection
Primjena injekcije
Do not mix ABASAGLAR with any other insulins or medicines.
ABASAGLAR se ne smije miješati s drugim inzulinima ni drugim lijekovima.
ABASAGLAR 100 units/mL solution for injection in a pre-filled pen, KwikPen, is a clear and colourless solution.
ABASAGLAR 100 jedinica/ml otopina za injekciju u napunjenoj brizgalici KwikPen je bistra i bezbojna otopina.
Hydrochloric acid (for pH adjustment) Sodium hydroxide (for pH adjustment) Water for injections
6.1 Popis pomoćnih tvari cinkov oksid metakrezol glicerol kloridna kiselina (za podešavanje pH) natrijev hidroksid (za podešavanje pH) voda za injekcije
• If the dose knob it is hard to push: - Pushing the dose knob more slowly will make it easier to inject.
• Ako Vam je teško pritisnuti gumb za doziranje:
Packs of 5 and 10 cartridges.
Dostupna su pakiranja od 5 i 10 uložaka.
Keep this medicine out of the sight and reach of children.
Kako čuvati lijek ABASAGLAR Lijek čuvajte izvan pogleda i dohvata djece.
Insulin label must always be checked before each injection to avoid medication errors between ABASAGLAR and other insulins.
Prije svake injekcije uvijek se mora provjeriti naljepnica na inzulinu kako ne bi došlo do medikacijske pogreške zbog zamjene lijeka ABASAGLAR i drugih inzulina.
3 mL solution in a cartridge (type 1 colourless glass) with a plunger (halobutyl rubber) and a disc seal (laminate of polyisoprene and halobutyl rubber) with aluminium seal.
3 ml otopine u ulošku (bezbojno staklo tipa 1) s klipom (halobutilna guma) te čepom u obliku pločice
- The pen dials 1 unit at a time.
- Brizgalica odmjerava dozu u koracima od 1 jedinice.
General disorders and administration site conditions Injection site reactions include redness, pain, itching, hives, swelling, or inflammation.
Reakcije na mjestu injiciranja uključuju crvenilo, bol, svrbež, koprivnjaču, oticanje ili upalu.
Pre-filled pens in use or carried as a spare may be stored for a maximum of 28 days up to 30°C and away from direct heat or direct light.
Brizgalice u uporabi ili rezervne brizgalice mogu se čuvati najdulje 28 dana na temperaturi do 30°C, zaštićene od izvora topline i izravne svjetlosti.
Step 9:
9. korak:
Step 7:
7. korak:
Insulin administration may cause insulin antibodies to form.
Primjena inzulina može uzrokovati stvaranje protutijela na inzulin.
Very rare side-effects (may affect up to1 in 10,000 people) In very rare cases, dysgeusia (taste disorders) and myalgia (muscular pain) can occur.
U vrlo rijetkim slučajevima mogu nastupiti promjena osjeta okusa (disgeuzija) i bol u mišićima
The pharmacokinetic and pharmacodynamic findings indicate that the effect of the subcutaneous injection with insulin glargine is principally based on exposure to M1. Insulin glargine and the metabolite M2 were not detectable in the vast majority of subjects and, when they were detectable their concentration was independent of the administered dose of insulin glargine.
Farmakokinetički i farmakodinamički nalazi pokazuju da se učinak supkutane injekcije inzulina glargina uglavnom temelji na izloženosti metabolitu M1. U najvećeg broja ispitanika inzulin glargin i metabolit
• Unused pens may be used until the expiration date printed on the label, if the pen has been kept in the refrigerator.
• Ako se čuvaju u hladnjaku, neupotrijebljene brizgalice mogu se upotrijebiti do roka valjanosti otisnutog na naljepnici.
• Carefully replace the outer needle shield.
• Pažljivo vratite vanjski zatvarač igle na iglu.
Step 10:
10. korak:
When given intravenously the elimination half-life of insulin glargine and human insulin were comparable.
Kod intravenske je primjene poluvrijeme eliminacije inzulina glargina i ljudskog inzulina bilo usporedivo.
You must always check the insulin label before each injection to avoid mix-ups between ABASAGLAR and other insulins.
Prije svake injekcije uvijek morate provjeriti naljepnicu na inzulinu kako bi se izbjegla zamjena lijeka ABASAGLAR i drugih inzulina.
IGF-1 receptor binding: The affinity of insulin glargine for the human IGF-1 receptor is approximately 5 to 8-fold greater than that of human insulin (but approximately 70 to 80-fold lower than the one of IGF-1), whereas M1 and M2 bind the IGF-1 receptor with slightly lower affinity compared to human insulin.
5 do 8 puta veći nego afinitet ljudskog inzulina (ali približno 70 do 80 puta manji nego afinitet IGF-1
You should contact your doctor for advice on driving if: - you have frequent episodes of hypoglycaemia, - the first warning symptoms which help you to recognise hypoglycaemia are reduced or absent.
- ako imate česte epizode hipoglikemije - ako su Vam prvi upozoravajući znakovi hipoglikemije slabije izraženi ili izostaju
In clinical studies, antibodies that cross-react with human insulin and insulin glargine were observed with the same frequency in both NPH-insulin and insulin glargine treatment groups.
U kliničkim je ispitivanjima učestalost križnih reakcija protutijela s ljudskim inzulinom i inzulinom glarginom bila podjednaka u skupinama liječenima NPH inzulinom i onima liječenima inzulinom glarginom.
Each mL contains 100 units insulin glargine (equivalent to 3.64 mg).
Jedan ml sadrži 100 jedinica inzulina glargina (što odgovara 3,64 mg).
ABASAGLAR").
(mialgija).
• Wipe the rubber seal with a swab.
• Gumeni zaštitni zatvarač obrišite tupferom.
For more information, see the box at the end of this leaflet.
Za dodatne informacije pogledajte uokvireni tekst na kraju ove upute o lijeku.
In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
U bolesnika s oštećenjem bubrežne funkcije potrebe za inzulinom mogu biti smanjene zbog smanjenog metabolizma inzulina.
Each mL contains 100 units insulin glargine* (equivalent to 3.64 mg).
Jedan ml sadrži 100 jedinica inzulina glargina* (što odgovara 3,64 mg).
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline, propoxyphene, salicylates, somatostatin anologues and sulphonamide antibiotics.
Tvari koje mogu pojačati učinak na snižavanje razine glukoze u krvi i povećati sklonost hipoglikemiji obuhvaćaju oralne antidijabetike, inhibitore angiotenzin konvertirajućeg enzima (ACE), dizopiramid,
The pen dials 1 unit at a time.
Brizgalica odmjerava dozu u koracima od 1 jedinice.
The pen cap must be put back on the pen after each injection in order to protect from light.
Nakon svake injekcije morate vratiti zatvarač na brizgalicu radi zaštite od svjetlosti.
Do not dilute it. Mixing or diluting may change the action of ABASAGLAR.
Miješanje ili razrjeđivanje može promijeniti djelovanje lijeka ABASAGLAR.
Examples include: - you inject too much insulin, - you miss meals or delay them, - you do not eat enough, or eat food containing less carbohydrate than normal (sugar and substances similar to sugar are called carbohydrates; however, artificial sweeteners are NOT
- ako preskočite ili odgodite obrok - ako ne jedete dovoljno ili jedete hranu koja sadrži manje ugljikohidrata nego što je uobičajeno
For information on the treatment of hypoglycaemia, see box at the end of this leaflet.
Za informacije o liječenju hipoglikemije, pogledajte uokvireni tekst na kraju ove upute o lijeku.
Lipodystrophy may occur at the injection site and delay local insulin absorption.
Na mjestu injekcije može doći do lipodistrofije, koja može odgoditi lokalnu apsorpciju inzulina.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS CARTRIDGE LABEL
PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE NALJEPNICA ULOŠKA
ABASAGLAR is administered subcutaneously.
ABASAGLAR se primjenjuje supkutano.
Children below 2 years of age The safety and efficacy of insulin glargine have not been established No data are available.
Sigurnost i djelotvornost inzulina glargina nisu ustanovljene.
Disposing of pens and needles
Zbrinjavanje brizgalica i igala
Step 1:
1. korak:
Effects of insulin glargine (once daily) on diabetic retinopathy were evaluated in an open-label 5 year NPH-controlled study (NPH given bid) in 1024 type 2 diabetic patients in which progression of retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by fundus photography.
u 1024 bolesnika sa šećernom bolešću tipa 2, u kojih je progresija retinopatije za 3 stupnja ili više na ljestvici ETDRS (Early Treatment Diabetic Retinopathy Study) bila ispitana fotografiranjem fundusa.
The pen should be used as recommended in the information provided.
Brizgalicu je potrebno koristiti sukladno preporukama navedenima u priloženim informacijama.
Step 2:
2. korak:
- The dose knob clicks as you turn it. - DO NOT dial your dose by counting the clicks because you may dial the wrong dose.
Dok se gumb za doziranje okreće, čuje se 'klik' - NEMOJTE odmjeravati dozu brojanjem 'klikova', jer biste mogli odmjeriti pogrešnu dozu - Doza se može promijeniti okretanjem gumba za doziranje u jednom ili drugom smjeru, sve dok ispravna doza ne bude u ravnini s pokazivačem doze.
• Do not recycle the filled sharps container.
• Pun spremnik za oštre predmete ne smije se reciklirati.
Preparing your Pen
Priprema brizgalice
There were no differences between insulin glargine and standard care for the two coprimary outcomes; for any component endpoint comprising these outcomes; for all-cause mortality; or for the composite microvascular outcome.
Nisu primijećene razlike između inzulina glargina i standardnog liječenja za dva primarna ishoda, za bilo koju mjeru koja je sastavnica navedenih ishoda,
• Pull the pen cap straight off.
• Povucite zatvarač ravno s brizgalice.
In healthy subjects and diabetic patients, insulin serum concentrations indicated a slower and much more prolonged absorption and showed a lack of a peak after subcutaneous injection of insulin glargine in comparison to human NPH insulin.
Apsorpcija Nakon supkutane injekcije inzulina glargina koncentracije inzulina u serumu zdravih ispitanika i dijabetičara ukazivale su na sporiju i značajno dulju apsorpciju te izostanak vršne koncentracije u usporedbi s ljudskim NPH inzulinom.
Do not add any other insulin to the cartridge.
U uložak se ne smije dodavati niti jedan drugi inzulin.
If you have proliferative retinopathy (an eye disease related to diabetes) severe hypoglycaemic attacks may cause temporary loss of vision.
Ako imate proliferativnu retinopatiju (bolest očiju povezanu sa šećernom bolešću),
Do not put ABASAGLAR next to the freezer compartment or a freezer pack.
ABASAGLAR se ne smije staviti neposredno uz zamrzivač ili rashladni uložak.
Do not store ABASAGLAR next to the freezer compartment or a freezer pack.
ABASAGLAR se ne smije čuvati neposredno uz zamrzivač ili rashladni uložak.
These include: - change in the injection area, - improved insulin sensitivity (e.g., by removal of stress factors), - unaccustomed, increased or prolonged physical activity, - intercurrent illness (e.g. vomiting, diarrhoea), - inadequate food intake, - missed meals, - alcohol consumption, - certain uncompensated endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary or adrenocortical insufficiency), - concomitant treatment with certain other medicinal products.
Oni obuhvaćaju: - promjenu područja injiciranja, - poboljšanu osjetljivost na inzulin (npr. uklanjanjem čimbenika stresa), - povećanu ili dugotrajnu tjelesnu aktivnost na koju bolesnik nije navikao, - interkurentnu bolest (npr. povraćanje, proljev),
Pens in use must not be stored in the refrigerator.
Brizgalice u uporabi ne smiju se odlagati u hladnjak.
Such reactions to insulin (including insulin glargine) or the excipients may, for example, be associated with generalised skin reactions, angiooedema, bronchospasm, hypotension and shock, and may be life-threatening.
Takve reakcije na inzulin (uključujući inzulin glargin) ili na pomoćne tvari mogu, primjerice, biti povezane s generaliziranim kožnim reakcijama,
The pen should be used as recommended in the information provided with the device.
Brizgalicu je potrebno koristiti sukladno preporukama navedenima u informacijama priloženima uz taj medicinski proizvod.
Step 13:
13. korak:
• Do not store the pen with the needle attached to prevent leaking, blocking the needle, and air from entering the pen.
• Da biste spriječili istjecanje inzulina, začepljenje igle i ulazak zraka u brizgalicu, ne smijete čuvati brizgalicu s pričvršćenom iglom.
Selecting your dose
Vašom dozom.
Step 11:
11. korak:
How to store ABASAGLAR
Kako primjenjivati lijek ABASAGLAR
Musculoskeletal and connective tissue disorders
Poremećaji mišićno-koštanog sustava i vezivnog tkiva mialgija
Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter.
Tijekom prijelaza i u prvim tjednima nakon toga preporučuje se pomno nadzirati metabolizam.
Empty pens must not be re-filled and must be properly discarded.
Prazne brizgalice ne smiju se ponovno puniti i moraju se propisno zbrinuti.
Injection sites must be rotated within a given injection area from one injection to the next.
Mjesto injiciranja mora se promijeniti kod svake injekcije unutar preporučenog područja primjene.
Switch from twice daily NPH insulin to ABASAGLAR To reduce the risk of nocturnal and early morning hypoglycaemia, patients who are changing their basal insulin regimen from a twice daily NPH insulin to a once daily regimen with ABASAGLAR should reduce their daily dose of basal insulin by 20-30 % during the first weeks of treatment.
Kako bi se umanjio rizik od noćne i ranojutarnje hipoglikemije, bolesnici koji mijenjaju režim liječenja bazalnim inzulinom s liječenja NPH inzulinom dvaput na dan na liječenje lijekom
Solution for injection (injection) in pre-filled pen (KwikPen) Clear, colourless solution.
Otopina za injekciju (injekcija) u napunjenoj brizgalici (KwikPen).
- all other medicines to treat diabetes, - angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure), - disopyramide (used to treat certain heart conditions), - fluoxetine (used to treat depression), - fibrates (used to lower high levels of blood lipids), - monoamine oxidase (MAO) inhibitors (used to treat depression), - pentoxifylline, propoxyphene, salicylates (such as aspirin, used to relieve pain and lower fever), - somatostatin analogues (such as octreotide, used to treat an uncommon condition in which you make too much growth hormone), - sulphonamide antibiotics.
- sve druge lijekove za liječenje šećerne bolesti - inhibitore angiotenzin konvertirajućeg enzima (ACE-inhibitore) (koriste se za liječenje nekih srčanih bolesti ili visokog krvnog tlaka) - dizopiramid (koristi se za liječenje nekih srčanih bolesti) - fluoksetin (koristi se za liječenje depresije) - fibrate (koriste se za snižavanje visoke razine masnoća u krvi)
Each millilitre of the solution contains 100 units of the active substance insulin glargine (equivalent to 3.64 mg).
Jedan mililitar otopine sadrži 100 jedinica djelatne tvari inzulina glargina (što odgovara 3,64 mg).
You can give yourself multiple doses using one pen.
Jednom brizgalicom možete primijeniti veći broj doza.
Dose Window
Prozorčić za odabir doze
Factors increasing the susceptibility to hypoglycaemia require particularly close monitoring and may necessitate dose adjustment.
Potrebno je osobito pomno nadzirati čimbenike koji povećavaju sklonost hipoglikemiji te prema potrebi prilagoditi dozu.
Insulin antibodies
Protutijela na inzulin
• Pull off the outer needle shield.
• Skinite vanjski zatvarač igle.
Step 4:
4. korak:
Troubleshooting
Doziranje
The dose indicator should line up with your dose.
Pokazivač doze mora biti u ravnini s
ABASAGLAR 100 units/mL solution for injection in a cartridge is a clear and colourless solution.
ABASAGLAR 100 jedinica/ml otopina za injekciju u ulošku je bistra i bezbojna otopina.
Read carefully the "ABASAGLAR KwikPen Instructions for Use" included with this package leaflet.
"Upute za uporabu brizgalice ABASAGLAR KwikPen", koje su sastavni dio ove upute o lijeku.
• Dose Knob:
• Gumb za doziranje:
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON - KwikPen.
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKA KUTIJA - KwikPen brizgalica.
Hypoglycaemia
HIPERGLIKEMIJA
Inspect the cartridge before use.
Pregledajte uložak prije nego što ga upotrijebite.
• Swab
• tupfer
Step 3:
3. korak:
Before travelling consult your doctor.
Obratite se svom liječniku za savjet prije putovanja.
Step 6:
6. korak:
Dose Indicator
Naljepnica Pokazivač doze
ABASAGLAR is a long-acting insulin.
ABASAGLAR je dugodjelujući inzulin.
The adverse reaction reports received from post marketing surveillance included relatively more frequent injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) in children and adolescents (≤ 18 years of age) than in adults.
U djece i adolescenata mlađih od 18 godina relativno su češće nego u odraslih bolesnika prijavljene pritužbe na reakcije na mjestu injiciranja (bol na mjestu injiciranja, reakcija na mjestu injiciranja) i kožne reakcije (osip, koprivnjača).
Paper Tab
Papirnati pokrov
The pen in use must not be stored in the refrigerator.
Brizgalica u uporabi ne smije se odlagati u hladnjak.
Instructions for use KwikPen ABASAGLAR 100 units/mL solution for injection in a pre-filled pen Insulin glargine
Upute za uporabu KwikPen ABASAGLAR 100 jedinica/ml otopina za injekciju u napunjenoj brizgalici inzulin glargin
However, only very rarely, this will require a change to your insulin dose.
Međutim, promjena doze inzulina bit će potrebna samo u vrlo rijetkim slučajevima.
There was less severe hypoglycaemia in the insulin glargine group as well.
Isto tako, u skupini koja je primala inzulin glargin bilo je manje slučajeva teške hipoglikemije.
ABASAGLAR 100 units/mL injection KwikPen insulin glargine
ABASAGLAR 100 jedinica/ml, injekcija KwikPen inzulin glargin s.c. primjena
• Put used needles in a closable, puncture-resistant sharps container.
• Upotrijebljene igle odložite u neprobojan spremnik za oštre predmete koji se može zatvoriti.
The exposure to M1 increases with the administered dose of insulin glargine.
Glavni cirkulirajući metabolit u plazmi je M1. Izloženost metabolitu M1 raste s primijenjenom dozom inzulina glargina.
Package leaflet: Information for the user ABASAGLAR 100 units/mL solution for injection in a cartridge insulin glargine
Uputa o lijeku: Informacije za korisnika ABASAGLAR 100 jedinica/ml otopina za injekciju u ulošku inzulin glargin
- diuretics (used to treat high blood pressure or excessive fluid retention), - glucagon (pancreas hormone used to treat severe hypoglycaemia), - isoniazid (used to treat tuberculosis), - oestrogens and progestogens (such as in the contraceptive pill used for birth control), - phenothiazine derivatives (used to treat psychiatric disorders), - somatropin (growth hormone), - sympathomimetic medicines (such as epinephrine [adrenaline], salbutamol, terbutaline used to treat asthma), - thyroid hormones (used to treat thyroid gland disorders), - atypical antipsychotic medicines (such as clozapine, olanzapine), - protease inhibitors (used to treat HIV).
- simpatomimetičke lijekove (poput epinefrina [adrenalina], salbutamola, terbutalina, koji se koriste za liječenje astme) - hormone štitnjače (koriste se za liječenje poremećaja štitnjače) - atipične antipsihotičke lijekove (kao što su klozapin, olanzapin) - inhibitore proteaze (koriste se za liječenje HIV infekcije)
Recap the pen after use to protect from light.
Nakon primjene vratiti zatvarač na brizgalicu radi zaštite od svjetlosti.
Dose
Baciti
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens, progestogens, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and olanzapine) and protease inhibitors.
somatropin, simpatomimetičke lijekove (npr. epinefrin [adrenalin], salbutamol, terbutalin), hormone štitnjače, atipične antipsihotike (npr. klozapin i olanzapin) te inhibitore proteaze.
Do not rub the area.
Ne smije se razrjeđivati.
Keep the cartridge in the outer carton in order to protect from light.
Uložak čuvati u vanjskom pakiranju radi zaštite od svjetlosti.
It must only be used if the solution is clear, colourless, with no solid particles visible, and if it is of water-like consistency.
bezbojna, vodenasta i ako nema vidljivih krutih čestica.
• You can give from 1 to 6080 units in a single injection.
• U jednoj injekciji možete injicirati najmanje 1, a najviše 60 80 jedinica.
Posology
Uložak
Lipoatrophy
retinopatija
Do not use ABASAGLAR if you notice particles in it. Only use ABASAGLAR if the solution is clear, colourless and water like.
ABASAGLAR se smije upotrijebiti samo ako je otopina bistra, bezbojna i vodenasta.
Package leaflet: Information for the user ABASAGLAR 100 units/mL solution for injection in a pre-filled pen insulin glargine
Uputa o lijeku: Informacije za korisnika ABASAGLAR 100 jedinica/ml otopina za injekciju u napunjenoj brizgalici inzulin glargin